Susquehanna International Group
MRNA icon

Susquehanna International Group’s Moderna MRNA Stock Holding History

Susquehanna International Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357M Sell
7,033,600
-4,301,800
-38% -$201M 0.04% 346
2025
Q4 		$334M Buy
11,335,400
+4,201,800
+59% +$114M 0.04% 370
2025
Q3 		$184M Buy
7,133,600
+1,726,900
+32% +$48.2M 0.02% 573
2025
Q2 		$149M Buy
5,406,700
+849,300
+19% +$22.4M 0.02% 561
2025
Q1 		$129M Sell
4,557,400
-1,690,800
-27% -$60M 0.02% 544
2024
Q4 		$260M Buy
6,248,200
+3,858,800
+161% +$184M 0.04% 345
2024
Q3 		$160M Buy
2,389,400
+26,600
+1% +$2.44M 0.03% 468
2024
Q2 		$281M Sell
2,362,800
-345,500
-13% -$43.7M 0.05% 264
2024
Q1 		$289M Sell
2,708,300
-624,800
-19% -$63M 0.05% 301
2023
Q4 		$331M Buy
3,333,100
+113,300
+4% +$9.53M 0.06% 252
2023
Q3 		$333M Buy
3,219,800
+1,077,400
+50% +$120M 0.07% 221
2023
Q2 		$260M Sell
2,142,400
-341,600
-14% -$45.6M 0.05% 278
2023
Q1 		$381M Sell
2,484,000
-1,539,800
-38% -$254M 0.08% 187
2022
Q4 		$723M Buy
4,023,800
+2,196,200
+120% +$359M 0.18% 81
2022
Q3 		$216M Sell
1,827,600
-668,400
-27% -$101M 0.06% 278
2022
Q2 		$357M Sell
2,496,000
-1,663,200
-40% -$238M 0.09% 168
2022
Q1 		$716M Sell
4,159,200
-1,180,500
-22% -$199M 0.12% 109
2021
Q4 		$1.36B Sell
5,339,700
-1,200,300
-18% -$351M 0.2% 69
2021
Q3 		$2.52B Buy
6,540,000
+416,300
+7% +$154M 0.34% 34
2021
Q2 		$1.44B Buy
6,123,700
+600
+0% +$107K 0.2% 60
2021
Q1 		$802M Sell
6,123,100
-538,000
-8% -$78M 0.13% 122
2020
Q4 		$696M Buy
6,661,100
+3,336,100
+100% +$338M 0.11% 122
2020
Q3 		$235M Buy
3,325,000
+735,100
+28% +$51.3M 0.05% 299
2020
Q2 		$166M Buy
2,589,900
+1,246,900
+93% +$68.3M 0.04% 348
2020
Q1 		$40.2M Buy
1,343,000
+1,149,600
+594% +$26.4M 0.01% 755
2019
Q4 		$3.78M Sell
193,400
-54,900
-22% -$974K ﹤0.01% 3360
2019
Q3 		$3.95M Buy
248,300
+69,500
+39% +$1.03M ﹤0.01% 3054
2019
Q2 		$2.62M Sell
178,800
-18,200
-9% -$391K ﹤0.01% 3678
2019
Q1 		$4.01M Buy
+197,000
New +$3.66M ﹤0.01% 2723

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's MRNA Position: Q1 2026 in Review

Susquehanna International Group reduced its Moderna (MRNA) stake by 97% in Q1 2026, selling an estimated $72.8M and leaving 54,840 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #5422.

Susquehanna International Group first reported a position in MRNA in Q4 2018 and has held it in 28 quarters since. The position peaked at $270M in Q3 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Susquehanna International Group held 54,840 shares of Moderna worth $2.79M as of Q1 2026.
  • Susquehanna International Group sold 1,560,559 Moderna shares in Q1 2026, an estimated $72.8M.
  • Moderna made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5422 holding.
  • Susquehanna International Group first reported a position in Moderna in Q4 2018 and has held it in 28 quarters since.
  • Susquehanna International Group's Moderna position peaked at $270M in Q3 2021.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.